scispace - formally typeset
J

Joaquín Bermejo

Publications -  8
Citations -  810

Joaquín Bermejo is an academic researcher. The author has contributed to research in topics: Retrospective cohort study & Carbapenem. The author has an hindex of 8, co-authored 8 publications receiving 603 citations.

Papers
More filters
Journal ArticleDOI

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Belén Gutiérrez-Gutiérrez, +93 more
- 01 Jul 2017 - 
TL;DR: Patients with BSIs due to CPE should receive active therapy as soon as they are diagnosed, and monotherapy should be considered for those in the low-mortality-score stratum.
Journal ArticleDOI

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Belén Gutiérrez-Gutiérrez, +38 more
- 01 Jul 2016 - 
TL;DR: BLBLIs, if active in vitro, appear to be as effective as carbapenems for ET and TT of BSI due to ESLB-E regardless of the source and specific species.
Journal ArticleDOI

A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

Belén Gutiérrez-Gutiérrez, +86 more
TL;DR: A validated score predictive of early mortality in patients with BSIs due to CPE was developed and exhibited an area under the receiver operating characteristic curve.
Journal ArticleDOI

Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae

Zaira R. Palacios-Baena, +38 more
- 01 Mar 2017 - 
TL;DR: An easy-to-collect predictive scoring model for all-cause 30 day mortality useful for identifying patients at high and low risk of mortality is developed and validated.
Journal ArticleDOI

Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.

Zaira R. Palacios-Baena, +85 more
- 30 Oct 2017 - 
TL;DR: It was unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems, but information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E.